Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-08043-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Laura C Pinheiro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, 420 E 70th Street, Box 331, New York, NY, 10065, USA. lcp2003@…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Breast Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
INTRODUCTION: Interstitial lung disease (ILD) is a serious side effect of certain mBC treatments, but our understanding of its prevalence outside of clinical trials and treatment-specific studies is limited. We sought to characterize the incidence of ILD among a large, population-based cohort of adults with mBC in the United States. METHODS: We included females and males aged 66 + years who were diagnosed with Stage IV breast cancer (as their first cancer) between January 1, 2002-December 31, 2017, using the SEER-Medicare linked. Our primary outcome was an incident ILD diagnosis after their mBC diagnosis, which was operationalized as a binary outcome. We examined demographic and clinical factors associated with incident ILD using logistic regression models. RESULTS: Among the 14,343 patients with mBC and no evidence of ILD at baseline, the median age at diagnosis was 76 (IQR 70, 82) years and 98% were female. Overall, 1,806 (12.6%) had an ILD diagnosis after mBC diagnosis. There was no significant difference in proportion of patients who received a pharmacologic treatment that carries the potential risk of ILD between patients who received an ILD diagnosis and those who did not (14% vs. 12%). CONCLUSIONS: ILD is prevalent in 12.6% of adults with mBC, yet oncology guidelines for monitoring for this intrusive and potentially fatal complication are sparse and non-specific. Patient education raising awareness of ILD symptoms and engaging primary care and pulmonary medicine in may improve patient outcomes and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, 420 E 70th Street, Box 331, New York, NY, 10065, USA. lcp2003@med.cornell.edu.
- Division of Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. lcp2003@med.cornell.edu.
- Cancer Prevention and Control Research Program, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA. lcp2003@med.cornell.edu.
- Division of Epidemiology, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
- Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Division of Survivorship, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Pinheiro, L. C., An, A., Landry, C. A., Tonorezos, E., & Aronson, K. I. (2026). Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08043-y
Vancouver
Pinheiro LC, An A, Landry CA, Tonorezos E, Aronson KI. Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08043-y
BibTeX
@article{Pinheiro2026,
author = {Pinheiro, Laura C and An, Anjile and Landry, Chrystal A and Tonorezos, Emily and Aronson, Kerri I},
title = {Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-08043-y}
}
EUVIMED